Article summary
This open-label Phase II secondary analysis (n=30) compared psilocybin-assisted therapy in people with cancer receiving systemic anticancer treatment and those who were not. A single 25-mg dose produced similar reductions in depressive symptoms and a similar safety profile in both groups, although all severe or serious adverse events occurred among those receiving cancer treatment and were judged unrelated to psilocybin.
Continue to the original publication for the complete article.